Technology | EP Mapping and Imaging Systems | May 03, 2018

FDA Clears Abbott's High-density Advisor HD Grid EP Mapping Catheter

The Abbott Advisor HD Grid Mapping Catheter, Sensor Enabled, allows high density electro mapping for transcatheter EP cardiac ablation procedures.

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the Abbott Advisor HD Grid Mapping Catheter, Sensor Enabled. The new electrophysiology (EP) mapping catheter design allows physicians to see things differently during transcatheter EP cardiac ablation procedures. This includes capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue. 

The new catheter is designed to capture information, such as the direction and speed of cardiac signals, which is often missed with traditional mapping catheters. The Advisor HD Grid offers a unique grid configuration that captures this information and enables the creation of high-density electro maps of cardiac tissue to support optimal treatment. The vendor said for the first time, physicians can see electrical signals that they may have missed using standard mapping catheters.

"At the University of Chicago Medicine, we are passionate about understanding and redefining arrhythmia mechanisms with higher resolution cardiac mapping. Abbott's Advisor HD Grid represents an important step in the development of next generation mapping catheters. With a flexible and soft design using magnetic sensor technology, the catheter helps capture signals previous catheters may have missed to support the creation of highly detailed 3D maps of the heart," said Roderick Tung, M.D., associate professor of medicine and director of cardiac electrophysiology at the University of Chicago Hospitals. "Innovation within the field of electrophysiology continues to evolve toward improving our ability to visualize arrhythmias in much greater detail, and we are confident that patient outcomes will improve as a result."

As an added benefit for physicians, the new mapping catheter was designed with Abbott's Sensor Enabled technology, which can help optimize the accuracy of the cardiac image and provide physicians additional flexibility when pairing the catheter with the EnSite Precision cardiac mapping system.

The Advisor HD Grid Mapping Catheter, Sensor Enabled received European CE mark approval in December 2017. The catheter has been used in 20 countries since its European launch and the company expects commercial use to begin across the U.S. in the coming months.

Arrhythmias are abnormal heart rhythms caused by improperly conducted electrical signals in the heart. In the U.S., more than 7 million people have an irregular heartbeat.[1] Abnormal heart rhythms, which include conditions such as atrial fibrillation, make the heart beat too fast, too slow or out of sync. In each case, the heart may pump blood less effectively which can cause a range of symptoms that disrupt a patient's quality of life. In some cases, cardiac arrhythmias can damage the heart or cause blood clots, strokes or cardiac arrest.

For people battling complex arrhythmias, physicians may use cardiac ablation therapy to create lesions on the heart to disrupt the electrical pathways causing the erratic heart beats. To ensure the best outcomes for their patients, physicians first need to identify which areas of the heart contain those pathways. Mapping catheters are critical to providing this insight — delivering an inside view of the heart so physicians can navigate cardiac anatomy to deliver more precise ablation therapy.

For more information:


1. Atrial Fibrillation Fact Sheet|Data & Statistics|DHDSP|CDC. (2017) [online] Available at: [Accessed 10 Nov. 2017].

Related Content

The Acutus Medical AcQBlate Force sensing ablation catheter.

The Acutus Medical AcQBlate Force sensing ablation catheter.

News | Ablation Systems | April 05, 2021
April 5, 2021 — Acutus Medical today announced initial U.S.
The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...